Want to see DHR full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.R&D spend has been steady and deliberately managed, underpinning the bioprocessing and product momentum management highlighted on the call, while SG&A is the primary source of OpEx volatility — periodic step‑ups and a pronounced mid‑2025 spike look like integration, seasonality or one‑offs rather than permanent cost creep. Management’s focus on DBS-driven efficiency and the $125M Masimo synergy plan (including ~ $50M of OpEx savings) is the key catalyst: SG&A normalization and realized OpEx synergies would lock in recent margin gains despite near‑term respiratory and China headwinds.
Date | Research and Development | Selling, General, and Administrative | Other |
|---|---|---|---|
Jun 30, 2026 | $412.00M | $2.07B | $0.00 |
Mar 31, 2026 | $387.00M | $1.86B | $0.00 |
Dec 31, 2025 | $438.00M | $2.03B | $0.00 |
Sep 30, 2025 | $378.00M | $1.99B | $0.00 |
Jun 30, 2025 | $403.00M | $2.36B | $0.00 |
Mar 31, 2025 | $379.00M | $1.86B | $0.00 |
Dec 31, 2024 | $442.00M | $2.02B | $0.00 |
Sep 30, 2024 | $383.00M | $2.06B | $0.00 |
Jun 30, 2024 | $391.00M | $1.87B | $0.00 |
Mar 31, 2024 | $368.00M | $1.81B | $0.00 |